ANAPTYSBIO (ANAB) Director John A. Orwin Converts RSUs to 1,300 Shares

What Happened

• Director John A. Orwin reported the conversion/settlement of 1,300 restricted stock units (RSUs) into 1,300 shares of ANAPTYSBIO common stock on September 15, 2026. The Form 4 shows an acquisition of 1,300 shares at $0.00 (code M — exercise/conversion of derivative) and a corresponding disposition of a derivative instrument for 1,300 shares at $0.00. Per the filing footnote, these RSUs settle for no consideration when vested.

Key Details

• Transaction date: 2026-09-15 (filed on 2026-09-17 — filing appears timely, within the standard 2 business-day window).
• Transaction code: M (exercise or conversion of a derivative instrument).
• Shares acquired: 1,300 at $0.00 (settled RSUs); derivative instrument disposed: 1,300 at $0.00.
• Price/value: $0.00 per share on settlement (RSUs converted for no cash payment).
• Shares owned after transaction: Not specified in the provided filing.
• Footnotes: F1 — each RSU converts to 1 share upon settlement for no consideration. F2 — RSUs vest 1/3 each on Sept 15 of 2024, 2025 and 2026, subject to continued service (this transaction reflects the 2026 vesting tranche).

Context

• This transaction reflects routine vesting/settlement of previously granted RSUs, not an open-market purchase or sale. No cash changed hands and there is no indication the shares were immediately sold. Vesting-based conversions like this are common compensation events and do not necessarily signal a change in insider sentiment.